Dr. Achebe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis Street
Boston, MA 02115Phone+1 617-732-5048Fax+1 617-732-5706
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
University of Port Harcourt College of Health ServicesClass of 1995
St Luke's University Hospital/Easton HospitalResidency, Internal Medicine
Certifications & Licensure
MA State Medical License 2005 - 2026
FL State Medical License 2020 - 2022
CT State Medical License 2003 - 2006- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Isoquercetin in Sickle Cell Anemia Start of enrollment: 2020 Dec 01
- Retrospective Real World Oxbryta® Data Collection and Analysis Study Start of enrollment: 2021 Mar 20
- A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises Start of enrollment: 2021 Oct 26
Roles: Principal Investigator
Publications & Presentations
PubMed
- 9 citationsImpact of Sickle Cell Trait on Morbidity and Mortality from Sars-Cov-2 InfectionLauren E. Merz, Kavita Mistry, Donna Neuberg, Revital Freedman, Gerda Menard
Blood Advances. 2020-11-05 - 59 citationsVoxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, pha...Jo Howard, Kenneth I. Ataga, Robert Clark Brown, Maureen Achebe, Videlis Nduba
The Lancet. Haematology. 2021-05-01 - 341 citationsA Phase 3 Randomized Trial of Voxelotor in Sickle Cell DiseaseElliott Vichinsky, Carolyn Hoppe, Kenneth I. Ataga, Russell E. Ware, Videlis Nduba
The New England Journal of Medicine. 2019-06-13
Press Mentions
SGLT2 Inhibitors Reduces Hospitalization for Heart Failure Regardless of Presence of DiabetesApril 11th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
